Traditional medicine diplomacy is emerging as a soft-power tool for India. Discuss with reference to BIMSTEC and WHO initiatives.

Traditional medicine diplomacy — the use of Ayurveda, Yoga and allied AYUSH systems as instruments of external outreach — has moved from cultural showcasing to institution-building. India's recent BIMSTEC and WHO engagements show its growing, though still uneven, soft-power value.

BIMSTEC: building a regional platform

• India hosted the Third BIMSTEC Conference on Traditional Medicine Knowledge, Genetic Resources and IPR in Goa (September 2026), organised by the Ministry of Ayush with AIIA Goa as nodal institute, alongside the second Nodal Group meeting [1].
• Delegates from all seven members deliberated documentation, access and benefit-sharing, prior informed consent and community rights [1].
• It followed the Centre of Excellence for Traditional Medicine announced at the 6th BIMSTEC Summit, Bangkok (April 2025), with cancer-care capacity building and AYUSH scholarships [2].
• Agenda-setting here lets India bridge Neighbourhood First and Act East through a low-cost, non-coercive vector.

The multilateral/WHO track

• The WHO Global Traditional Medicine Strategy 2025–2034, adopted at WHA78 (May 2025), mainstreamed traditional medicine; India committed US$3 million to classifying traditional practices in global health frameworks [3].
• The WIPO Treaty on IP, Genetic Resources and Associated Traditional Knowledge (2024) mandates disclosure of country of origin, vindicating India's long anti-biopiracy stand [4].
• The TKDL operationalises this defence; after the CSIR–INPI (Brazil) agreement, 18 patent offices can access it [5].

Limits to the soft power

• Outcome documents are non-binding; consensus-driven BIMSTEC delivers slowly — its FTA, negotiated since 2004, remains unfinished [6].
• WHO places evidence-building first, implying promotion currently outpaces clinical validation [3].
• TKDL only blocks wrong patents; benefit-sharing awaits the WIPO treaty's 15 ratifications [4], and no BIMSTEC patent office has TKDL access yet [5].

India's traditional medicine diplomacy is thus a credible but still maturing asset — strongest where it converts summit announcements into standards, databases and treaty ratifications. Extending TKDL access to BIMSTEC patent offices and aligning the Centre of Excellence with WHO's evidence agenda would convert goodwill into durable regional public good.